Jun 08, 2020
Neurelis Announces Rapid and Broad Payer Coverage of the Company's Flagship Product, VALTOCO® (Diazepam Nasal Spray)
May 20, 2020
Neurelis Announces Total Of Nine Poster Presentations For The AANN, AMCP, And AAN Annual Meetings
May 04, 2020
Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors
Mar 02, 2020
Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue
Jan 13, 2020
Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption
Oct 15, 2019
Diazepam Market To Reach USD 1.27 Billion By 2026 | Reports And Data
Jun 04, 2019
Aquestive Therapeutics Completes Enrollment in Libervant(TM) (diazepam buccal film) Crossover Study
Apr 29, 2019
Neurelis Announces Two Poster Presentations At The Annual Meeting Of The American Academy Of Neurology
Apr 22, 2019
Neurelis Announces Completion Of Senior Management Team Buildout To Support The Anticipated Commercial Launch Of VALTOCO(TM)
Mar 06, 2019
Okayama University Research: Inflammation in the Brain Enhances the Side-effects of Hypnotic Medication
Dec 03, 2018
Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy
Oct 25, 2018
Aquestive Therapeutics Announces Completion of Diazepam Buccal Film Adult Epilepsy Monitoring Unit (EMU) Clinical Study with Positive Topline Results
Jan 25, 2018
CCHR: Another Celebrity Lost to Benzodiazepines and Opioids Mix
Nov 07, 2017
Neurelis Expands Worldwide Patent Portfolio With Latest Issuance In Japan